Uncategorized
Genentech completes enrollment in two phase 3 lampalizumab studies
Patient enrollment has been completed in two phase 3 trials of lampalizumab, which is being investigated for reducing the progression of geographic atrophy lesions secondary to age-related macular degeneration, according to correspondence from Genentech.The Chroma and Spectri trials are identical double-masked, sham-controlled studies with 1,881 patients at close to 300 locations in more than 20 countries, the correspondence said.